Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors
Background Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.Methods The National Library of Medicine’s Clinical Trials database was queried for phase III trials of lung, co...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2025.2458415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576374920970240 |
|---|---|
| author | Tianyi Wang Dinorah J Villanueva Ambily Banerjee Dina Gifkins |
| author_facet | Tianyi Wang Dinorah J Villanueva Ambily Banerjee Dina Gifkins |
| author_sort | Tianyi Wang |
| collection | DOAJ |
| description | Background Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.Methods The National Library of Medicine’s Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers. A reference population was identified from the Surveillance, Epidemiology, and End Result (SEER) database, covering 48% of the US population.Results Among 181 trials, race and ethnicity data were included in 86.7% and 60.2% of trials, respectively, with improving reporting over time. Participants were predominantly White (76.3%), followed by Asian/Pacific Islander (14.1%), Black/African American (4.5%), and American Indian/Alaska Native (0.6%). Hispanic/Latino constituted 6.4% of participants. The proportion of non-White groups increased from 19.4% in trials started before 2011 to 26.2% after 2015. Compared with SEER data, the percentages were lower for Asian/Pacific Islander across all cancers, Black/African American in breast and prostate cancers, American Indian or Alaska Native in colorectal, breast, and prostate cancers in US solely trials.Conclusions Reporting and enrollment of racial and ethnic minorities in trials remain inadequate but improving. To enhance diversity, real-world data are warranted to identify recruitment goals by better assessing the geographic distribution within the patient population. |
| format | Article |
| id | doaj-art-e13c4d6000b6466da4c0c2d889e956e0 |
| institution | Kabale University |
| issn | 2056-5623 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-e13c4d6000b6466da4c0c2d889e956e02025-01-31T06:26:31ZengTaylor & Francis GroupFuture Science OA2056-56232025-12-0111110.1080/20565623.2025.2458415Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumorsTianyi Wang0Dinorah J Villanueva1Ambily Banerjee2Dina Gifkins3Janssen Research & Development LLC, Raritan, NJ, USAJanssen Research & Development LLC, Miami, FL, USAJanssen Cilag, UKJanssen Research & Development LLC, Raritan, NJ, USABackground Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.Methods The National Library of Medicine’s Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers. A reference population was identified from the Surveillance, Epidemiology, and End Result (SEER) database, covering 48% of the US population.Results Among 181 trials, race and ethnicity data were included in 86.7% and 60.2% of trials, respectively, with improving reporting over time. Participants were predominantly White (76.3%), followed by Asian/Pacific Islander (14.1%), Black/African American (4.5%), and American Indian/Alaska Native (0.6%). Hispanic/Latino constituted 6.4% of participants. The proportion of non-White groups increased from 19.4% in trials started before 2011 to 26.2% after 2015. Compared with SEER data, the percentages were lower for Asian/Pacific Islander across all cancers, Black/African American in breast and prostate cancers, American Indian or Alaska Native in colorectal, breast, and prostate cancers in US solely trials.Conclusions Reporting and enrollment of racial and ethnic minorities in trials remain inadequate but improving. To enhance diversity, real-world data are warranted to identify recruitment goals by better assessing the geographic distribution within the patient population.https://www.tandfonline.com/doi/10.1080/20565623.2025.2458415Raceethnicityclinical trialneoplasmsSEER program |
| spellingShingle | Tianyi Wang Dinorah J Villanueva Ambily Banerjee Dina Gifkins Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors Future Science OA Race ethnicity clinical trial neoplasms SEER program |
| title | Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors |
| title_full | Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors |
| title_fullStr | Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors |
| title_full_unstemmed | Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors |
| title_short | Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors |
| title_sort | reporting and representation of participant race and ethnicity in phase iii clinical trials for solid tumors |
| topic | Race ethnicity clinical trial neoplasms SEER program |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2025.2458415 |
| work_keys_str_mv | AT tianyiwang reportingandrepresentationofparticipantraceandethnicityinphaseiiiclinicaltrialsforsolidtumors AT dinorahjvillanueva reportingandrepresentationofparticipantraceandethnicityinphaseiiiclinicaltrialsforsolidtumors AT ambilybanerjee reportingandrepresentationofparticipantraceandethnicityinphaseiiiclinicaltrialsforsolidtumors AT dinagifkins reportingandrepresentationofparticipantraceandethnicityinphaseiiiclinicaltrialsforsolidtumors |